Compare MATH & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MATH | CRDL |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Hong Kong | Canada |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.8M | 97.3M |
| IPO Year | N/A | N/A |
| Metric | MATH | CRDL |
|---|---|---|
| Price | $1.95 | $0.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 48.0K | ★ 325.4K |
| Earning Date | 03-06-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $44,567,257.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.95 | ★ N/A |
| Revenue Growth | ★ 165.86 | N/A |
| 52 Week Low | $1.25 | $0.77 |
| 52 Week High | $4.17 | $1.59 |
| Indicator | MATH | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 36.11 | 43.67 |
| Support Level | $1.90 | $0.98 |
| Resistance Level | $2.09 | $0.99 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 9.62 | 21.87 |
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.